Christopher P. Fox

A match-adjusted indirect treatment comparison of lenalidomide plus rituximab versus rituximab plus chemotherapy for relapsed and/or refractory follicular lymphoma.

Purpose of the Study: The RELEVANCE trial found similar efficacy and a different safety profile for lenalidomide plus rituximab (R2) com- pared with rituximab plus chemotherapy (R-chemo) ...

Safiya Abouzaid ;

Claire Watkins ;

Emmanuel Bachy ;

Christopher P. Fox ;

Luca Arcaini ;

Grancisco Hernandez-Ilizaliturri ;

Ashley Tabah ;

Christopher Parker ;

Jeffrey Jones ;

10/22/2019

Subcutaneous Epcoritamab Versus Standard of Care in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase 3 EPCORE DLBCL-1 Trial

Introduction:

Christopher P. Fox ;

Michael Roost Clausen ;

Catherine Thieblemont ;

Pieternella Lugtenburg ;

Jun Wu ;

Anna S. Balari ;

Laura Finn ;

Signe D. Vindeløv ;

Pier Luigi Zinzani ;

11/04/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

November 8

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Christopher P. Fox

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products